What Is the Status of the Dupixent Lawsuit in Wyoming?

Super Lawyers® 2014–2024(888) 348-2735

Dupixent — CTCL Litigation

The Dupixent Litigation, Explained

Federal cases are consolidated in MDL 3180, most cases are in their earliest stages, and no settlement exists. Here is what is publicly known.

ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · deadlines vary by state.

Marin & Murphy is not licensed in Wyoming; details below.

Partners

Stefanie A. Murphy & Matthew T. Marin

Super Lawyers® honorees · members of the American Association for Justice · concentrating in personal injury and mass-tort litigation.

No settlement has been reached in the Dupixent litigation, and most cases are in their earliest stages. Every case must be proven on its own facts. Whether any patient has a claim depends on the facts and the law of their state. The information below covers the litigation itself.

Marin & Murphy Law Firm is not licensed in Wyoming; details below.

Where Things Stand in the Dupixent CTCL Litigation

In Wyoming as nationwide, Dupixent (dupilumab) — a prescription biologic made by Sanofi and Regeneron, FDA-approved since March 2017 — now carries nine indications, including atopic dermatitis, asthma, and COPD. For Wyoming claimants, the operative order came in June 2026, when the Judicial Panel on Multidistrict Litigation centralized the pending federal cases as MDL 3180 in the United States District Court for the District of New Jersey, before Judge Zahid N. Quraishi. The complaints in the consolidated Dupixent lawsuit allege that the drug is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn patients and doctors. The MDL that would receive a case from Wyoming counted at least 36 identified member cases as of September 15, 2026; the MDL 3180 tracker keeps the current count and its method. No court has ruled on the merits of any Dupixent claim — from Wyoming or anywhere else — and no settlement exists.

What the Filings Allege — and What They Do Not

An association is alleged; no court, in Wyoming or elsewhere, has adjudicated it as fact. Published studies report a statistical association between dupilumab and CTCL — an association the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal for CTCL that it is still evaluating. Dupixent’s label — the same label patients in Wyoming see — currently contains no lymphoma or malignancy warning. The FDA adverse event reports connected to this question are agency reports, not verified causes, and the courts have decided nothing on the merits — in Wyoming or anywhere else.

Who Is Included in the Filed Dupixent Cases? — Wyoming

Every Dupixent CTCL lawsuit filed in federal court now proceeds in one place, MDL 3180 in the District of New Jersey, regardless of where the plaintiff lives. Public docket indexes do not reliably show which member cases were brought by Wyoming residents: most complaints in the MDL are not available in the free public record, and the court a case was filed in says little about the plaintiff’s home state. Rather than guess, this page states what the record supports. The MDL 3180 tracker carries the current case count, how it is counted, and the latest docket activity; when a Wyoming resident’s complaint becomes publicly available, this section will describe it.

Who the Filed Cases Include

For Wyoming families reviewing the criteria: the consolidated cases involve Dupixent use followed by a diagnosis of cutaneous T-cell lymphoma or a related T-cell lymphoma subtype during or after that use. There is no minimum length of Dupixent use required; in Wyoming, estates of patients who have died bring claims under state wrongful-death and survival statutes. Whether any individual’s circumstances resemble the filed cases is a question of medical records and state law, not of headlines — and for a Wyoming resident, it is a question for an attorney licensed in Wyoming.

Wyoming’s Federal Courts and the Path to MDL 3180

Wyoming has one federal district court: the United States District Court for the District of Wyoming. No Dupixent CTCL lawsuit filed there proceeds alone — the Judicial Panel on Multidistrict Litigation has centralized these cases as MDL 3180 before Judge Zahid N. Quraishi in the United States District Court for the District of New Jersey, so a Wyoming case is transferred to the MDL for coordinated pretrial proceedings — or, where the MDL court’s case-management orders permit, filed in the District of New Jersey directly. Both routes end in the same consolidated proceeding; every case, including any from Wyoming, remains an individual claim — an MDL is not a class action.

Filing Deadlines Under Wyoming Law

Wyoming’s general statute of limitations for personal-injury claims is four years under Wyo. Stat. § 1-3-105(a)(iv)(C). Wyoming applies a discovery rule: accrual occurs when the plaintiff knows or has reason to know that damage resulted from a wrongful act. How a limitations period applies to any specific CTCL diagnosis depends on the dates in the medical records, the legal theory pleaded, and Wyoming tolling and accrual doctrine. An attorney licensed in Wyoming can evaluate whether a claim is timely.

A wrongful-death claim carries a two-year period that begins at death (Wyo. Stat. § 1-38-102(d)), brought by the estate’s representative.

How Common Is CTCL in Wyoming?

Wyoming is home to about 600,000 people (U.S. Census Bureau, 2024 estimate). Cutaneous T-cell lymphoma is rare — roughly 8.55 new cases per million person-years (SEER) — which works out to on the order of 5 new CTCL diagnoses across Wyoming in a typical year. That rarity is why no statistic on this page can answer an individual question from Wyoming: medical records, read against state law, decide any single claim.

About Marin & Murphy Law Firm and Wyoming

Marin & Murphy Law Firm is a personal-injury and mass-tort law firm; its attorneys’ individual admissions are listed at the bottom of this page, and this page is published as litigation information. Marin & Murphy Law Firm is not licensed in Wyoming. The firm does not accept Wyoming legal matters; inquiries from Wyoming residents are referred to attorneys licensed in Wyoming. Some matters may be referred to other lawyers. An attorney licensed in Wyoming can evaluate whether a claim is timely and how Wyoming law applies to a particular diagnosis.

Wyoming Dupixent Litigation FAQs